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Abstract
Background: Innate defence mechanisms of the airways are impaired in chronic obstructive pulmonary disease
(COPD), predisposing patients to lower respiratory tract infections, but less is known about the association with
other infections. In this population-based cohort study, we investigated the associations between COPD and invasive
bacterial disease by comparing incidence rates of bacteraemia in COPD patients and randomly selected reference
individuals from the general population.
Methods: In this population based cohort study all patients with COPD, ≥40 years of age, who were discharged
from hospitals in southern Sweden between 1990 and 2003 were identified in the Swedish Inpatient Register
(n = 15,403). Age and gender matched reference individuals were randomly selected from the general population.
Records were cross-referenced to the microbiological databases covering the region, 1990–2010. The hazard ratios
(HR) of bloodstream infections and hospitalisations for infections were estimated by Cox proportional hazards
regression.
Results: We found that individuals with COPD had a 2.5-fold increased incidence of bacteraemia compared to the
reference individuals from the general population adjusted for other co-morbidity and socio-economic status
(hazard ratio: 2.5, 95% confidence interval: 2.2-2.7). The increased incidence of bacteraemia was paralleled by an
increased incidence of hospitalisation for non-respiratory infections, i.e., skin infections, pyelonephritis, or septic
arthritis. Despite higher absolute rates of bloodstream infections among COPD patients than among the general
population, the distribution of different pathogens was similar.
Conclusions: In summary this population-based study shows COPD is associated with an increased incidence of
invasive bacterial infections compared to the general population, indicating a general frailty of acquiring severe
infections in addition to the specific susceptibility to infections of respiratory origin. The underlying contributory
factors (e.g. smoking, corticosteroid use, co-morbid diseases or a frailty inherent to COPD itself) need to be
disentangled in further studies.
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Background
The prevalence of chronic obstructive pulmonary disease
(COPD) is increasing worldwide, and it is estimated that
COPD will become the third leading cause of death in
2020 [1]. In Sweden, approximately 500,000 individuals
out of a population of 9 million suffer from COPD [2],
and approximately 2,500 die from the disease annually [3].
The healthy lung has a range of defence mechanisms
that protect the lower respiratory airways against invading
microbial pathogens. In COPD, several of these mecha-
nisms are impaired [4], which predisposes patients to
both acute and chronic lower respiratory tract infections
[5]. While the association between COPD and respiratory
infections has been extensively studied, less is known
about the associations between COPD and other types
of severe infections.
COPD is a well known risk factor for invasive disease
from Streptocccus pneumoniae and has been suggested
to be associated with invasive disease from Pseudomonas
aeruginosa [6,7]. Whether the incidence of invasive bac-
terial infections from other pathogens associated with
COPD, e.g., Haemophilus influenzae, is also increased or
whether COPD patients have a general susceptibility to
invasive bacterial infections is not known.
In the present population-based cohort study, COPD
patients and randomly selected reference individuals from
the general population living in southern Sweden, an
area with approximately 1.2 million inhabitants, were
compared to investigate whether underlying COPD af-
fected the risk of acquiring invasive bacterial infections,




Swedish health care is publicly financed, and all inpatient
care is provided independently of health insurance and
the patient’s financial status.
Case retrieval and control selection
All individuals ≥ 40 years of age living in the county of
Skåne with a hospital discharge diagnosis of COPD ac-
cording to the International Classification of Diseases
(Ninth version: 491–492, 496; Tenth version: J41-J44)
1990–2003, either as a main or additional diagnosis, were
identified in the Swedish Inpatient Registry. These will
be referred to as “COPD-patients”. For each individual,
Statistics Sweden randomly selected one reference individ-
ual from the general population in the Total Population
Registry matched for gender, year of birth, and county of
residence at 31 December of the preceding year of the first
hospital discharge listing a COPD diagnosis. A unique,
lifelong ten-digit personal identification number assigned
to each person living in Sweden provides the possibility of
cross-referencing in national databases.
All COPD-patients and general population controls
were linked to national databases to obtain information
on vital status, date of emigration, and socio-economic
status. Information on co-morbidity was obtained through
linkage with the national Inpatient Registry and the Cancer
Registry. Co-morbidity was defined as a prior hospital
discharge diagnosis of diabetes mellitus, kidney failure,
cardiac disease, alcohol-related disease, liver failure,
connective tissue disease, immune-deficiency, total num-
ber of hospitalizations and total duration of hospital stay
before inclusion. In addition a diagnosis of haematological
or solid cancer in the Cancer Registry up to five years
before inclusion was noted (see Appendix for specific
ICD-codes). The study was approved by the Lund University
Research Ethics Committee (590/2004 and 270/2012).
Follow-Up
The records were cross-referenced to the databases of all
microbiological laboratories in the region to obtain in-
formation on all blood cultures with growth. Follow-up
started 30 days after the first hospitalization with COPD
and on the corresponding date for the reference individuals
and ended on the date of emigration, date of death or at 31
December 2010, whichever came first. Individuals were not
considered at risk less than 30 days after an episode for all
outcomes except endocarditis and septic arthritis were a
lag time of 60 days was used due to long treatments. In
addition, information on all hospital discharge diagnoses
between 1990 and 2010 was obtained.
Statistical analysis
The incidence rates for pooled bloodstream infections, in-
fections with specific bacterial species and hospitalization
for infections during follow-up were calculated. Relative
ratios for the association with COPD and first subsequent
infection were estimated using Cox proportional hazards
models. All models were internally stratified by year of
birth, age and gender, using time since inclusion as the
timescale, and were subsequently adjusted for socio-
economic status and co-morbidity at baseline. Interactions
between COPD status and age at inclusion, gender, and
prior hospitalization on outcome were tested by entering
interaction terms in the fully adjusted Cox models. Pro-
portionalities of hazards were assessed graphically and
by the method using Schoenfeld residuals [8]. All ana-
lyses were performed using STATA/SE (version 10.1 for
Windows; StataCorp LP, College Station, USA).
Results
Study population and exclusions
A total of 17,955 individuals with a discharge diagnosis of
COPD were identified. Among these, 54 (0.3%) individuals
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were excluded because of data irregularities, and 1,754
(9.8%) individuals who died before the start of follow-up
(<30 days after the date of inclusion) were also excluded.
Because reference individuals were randomly selected
from the background population, some of these also
appeared as COPD patients during follow-up. Among
the reference individuals, we excluded 449 (2.5%) who
died before the start of follow-up and 362 (2.0%) who
had been hospitalised with a COPD diagnosis prior to
inclusion. An additional 930 (5.2%) reference individuals
were included in the analysis but censored by the date of
the first hospitalization listing COPD.
Due to the matched design 744 (4.1%) COPD patients
lacking controls due to exclusions and 1,741 (9.7%) con-
trols were excluded. Analysis was based on the remaining
15,403 case–control pairs. Baseline characteristics of the
study populations are shown in Table 1.
Bloodstream infections
In the 30,806 cases and controls, a total of 2,137 episodes
of bloodstream infections occurred (1,265 episodes in
1,105 COPD patients and 872 episodes in 759 reference
individuals) during 87,258 and 140,063 person-years of
follow-up, respectively. Bacterial species of commensal
skin flora (e.g., coagulase-negative staphylococci, Coryne-
bacteriaceae and Propionibacteriaceae) were considered
as contaminants and not included.
The resulting crude incidence rates were 145.0 /10,000
person-years of follow-up (95% confidence interval [95%
CI] 137.2 to 153.2) in COPD patients and 62.3 (95% CI
58.3 to 66.5) in reference individuals, (see Table 2). Median-
time to first episode was 4.3 years in COPD-patients and
6.7 years in reference individuals, the cumulative incidences
are shown in Figure 1. This corresponds to a 2.5-fold in-
creased risk of time to first episode as estimated by Cox
regression (stratified by age, gender and year of birth and
adjusted for co-morbidity and socio-economic status), as
outlined in Table 3.
The absolute incidence increased with age, but the rela-
tive risk decreased with increasing age group (p = 0.01
from likelihood ratio test for interaction) (see Table 2).
There was no evidence of an interaction with gender
(p = 0.5 from interaction test).
A sensitivity analysis, using an in-patient control group,
restricted to those pairs of COPD patients and controls in
which the reference individual had been hospitalised prior
to inclusion (n = 18,148), yielded slightly more conservative
estimates, adjusted HR of 2.2 (95% CI 2.0-2.5) (p = 0.01
from interaction test). The mean age in this group was
higher than in those with no previous hospitalization (74.6
(SD 9.9) vs. 69.7 (SD 10.3), p = 0.01). In secondary analysis,
subjects were stratified according to the total number of
co-morbidities predisposing to severe infections, which also
yielded similar results, adjusted HR 2.4 (95% CI 2.2-2.7).
A sensitivity analysis, treating co-morbidity covariates
as time-dependent (i.e. co-morbidity status up to first
episode of bacteraemia) yielded similar results, adjusted
HR of 2.2 (95% CI 2.0-2.5). A sensitivity analysis exclud-
ing COPD patients with concurrent asthma discharge
diagnosis showed identical results. Rerunning analyses
not censoring control subjects with subsequent COPD
diagnosis yielded similar results (adjusted HR: 2.3; 95%
CI: 2.1-2.6).
Table 1 Demographic characteristics of the study
population
COPD patients
n = 15,403 (100%)
Reference individals1





40-59 1,858 (12.1%) 1,858 (12.1%)
60-79 9,346 (60.7%) 9,346 (60.7%)
≥80 4,199 (27.3%) 4,199 (27.3%)
Gender NA




Non-manual 2,569 (16.7) 3,684 (23.9)
Manual 4,473 (29.0) 4,002 (26.0)
Other 1,646 (10.7) 1,767 (11.5)
Outside workforce 2 6,715 (43.6) 5,950 (38.6)
Co-morbidity3
Diabetes mellitus 966 (6.3) 557 (3.6) <0.01
Kidney failure 107 (0.7) 42 (0.3) <0.01
Cardiac disease 3,775 (24.5) 1,993 (12.9) <0.01
Alcohol-related
disease
573 (3.7) 159 (1.0) <0.01
Liver failure 96 (0.6) 59 (0.4) <0.01
Connective tissue
disease
428 (2.8) 210 (1.4) <0.01
Immunodeficiency 57 (0.4) 23 (0.2) <0.01
HIV 8 (0.05) 2 (0.01) 0.06
Solid cancer 1,322 (8.6) 759 (4.9) <0.01
Hematological
cancer




37.7 / 12 22.5 / 3 <0.01
No. of discharges,
all diagnoses
4.4 / 2 2.2 / 1 <0.01
1−Control subjects were matched for year of birth, gender and county of
residence by the 31st of December of the year before first hospital
discharge listing a COPD diagnosis; 2−Subjects with missing information on
socio-economic status were mainly older pensioners, unemployed, disability
pensioners, homemakers and students: 3-Comorbidity was based on
discharge codes in the Inpatient Register before inclusion; see Appendix for
specific ICD codes.
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Distribution of pathogens
Despite higher absolute rates of bloodstream infections
among COPD patients than among reference individuals,
the distribution of different pathogens was similar. COPD
patients had a larger proportion of S. pneumoniae (11.2%
vs. 6.1%) and S. aureus (13.5% vs. 12.8%) and a corre-
sponding smaller proportion of Enterobacteriaceae com-
pared to controls subjects (42.0% vs. 48.5%). Specific
incidence rates and the corresponding HRs are presented
in Table 2.
Table 2 Age-specific incidence rates of bacteremia for individuals previously discharged with a COPD diagnosis and
reference individuals from the general population
COPD-patients Control Subjects
Pathogen N (%)1 Incidence 2 N (%) 1 Incidence 2 HR (95% CI)3
Pooled bloodstream infections 1,265(100) 145.0 (137.2-153.2) 872 (100) 62.3 (58.3-66.5) 2.5 (2.2-2.7)
40-59 years 157 (12.4) 87.4 (74.8-102.2) 68 (7.8) 29.1 (22.9-36.9) 3.1 (2.2-4.3)
60-79 years 850 (67.2) 154.0 (144.0-164.7) 573 (65.7) 61.5 (56.7-66.8) 2.6 (2.3-3.0)
≥80 years 258 (20.4) 183.0 (162.0-206.8) 231 (26.5) 98.2 (86.3-111.7) 1.9 (1.5-2.3)
Staphylococcus aureus 183 (13.5) 21.0 (18.1-24.2) 127(12.8) 9.1 (7.7-10.8) 2.4(1.8-2.9)
Streptococcus pneumoniae 157 (11.2) 18.0 (15.4-21.0) 60(6.1) 4.3 (3.3-5.5) 4.1 (3.0-5.7)
Pseudomonas aeruginosa 45 (3.2) 5.2 (3.9-6.9) 26 (3.0) 1.9 (1.3-2.7) 3.0 (1.8-5.2)
Enterobacteriacea4 985 (42.0) 112.9 (106.0-120.2) 786 (48.5) 56.2 (52.3-60.2) 2.1 (1.9-2.5)
Enterococci 94 (7.2) 10.8 (8.8-13.1) 74 (8.2) 5.3 (4.2-6.6) 1.9 (1.3-2.6)
Streptococcus pyogenes 22 (1.6) 2.5 (1.7-3.8) 15 (1.6) 1.1 (0.6-1.8) 2.8 (1.4-5.6)5
Haemophilus influenzae 10 (0.7) 1.1 (0.6-2.1) 7 (0.7) 0.5 (0.2-1-0) 2.8 (1.0-7.7)5
Moraxella catarrhalis 1 NA 0 NA NA
1-Percentage of total blood cultures with growth in either COPD patients or control subjects. 2- Total (crude) incidence of bloodstream infections per
10,000 person-years of follow-up. Infectious episodes were separated by <30 days.3-Hazard ratio of time to first bloodstream infection estimated by Cox
regression using time since inclusion as the time scale and stratified for age, year of birth and gender and adjusted for socio-economic position and
co-morbidity conferring increased risk of severe bacterial infections. 4-E. coli, Citrobacter spp., Enterobacter spp., Klebsiella spp., Providencia spp., Proteus
spp., Serratia marcescens.; 5-Due to the limited number of outcomes, this Cox model was only adjusted for total days spent in the hospital prior
to inclusion.
Figure 1 Cumulative incidence proportions for bloodstream
infections for patients hospitalised with a COPD diagnosis and
control subjects from the general population. Individuals were
censored on the first episode of bloodstream infection.
Table 3 Hazard ratios for bacteraemia for underlying
medical conditions, total use of inpatient care and





COPD 2.8 (2.5- 3.0) 2.5 (2.2-2.7)
Diabetes mellitus 2.4 (2.0-2.8) 1.7 (1.4-2.0)
Kidney failure 7.7 (5.0-11.8) 4.7 (3.0-7.5)
Cardiac disease3 1.7 (1.5-1.9) 1.2 (1.0-1.3)
Alcohol-related disease 2.0 (1.5-2.7) 1.2 (0.9-1.6)
Liver failure 2.7 (2.0-3.5) 2.3 (1.4-3.7)
Connective tissue disease 2.9 (1.8-4.6) 1.8 (1.4-2.4)
Immunodeficiency 3.8 (2.1-6.7) 1.8 (1.0-3.3)
Solid cancer 1.5 (1.2-1.8) 1.3 (1.1-1.6)
Hemathological cancer 5.6 (3.5-8.8) 4.7 (2.9-7.5)
Total days in hospital4 1.0 (1.0-1.0) 1.0 (1.0-1.0)
Total no. of discharges, all diagnoses5 1.6 (1.5-1.7) 1.2 (1.1-1.3)
Socio-economic position
Non-manual 1 1
Manual 1.2 (1.1-1-4) 1.1 (0.9-1.3)
Other 1.2 (1.0-1.4) 1.1 (1.0-1.3)
Missing 1.4 (1.2-1.7) 1.3 (1.1-1-5)
1- Hazard ratio of time to first bloodstream infection, having the condition
compared to not having the condition, estimated by Cox regression using
time since inclusion as the time scale and stratified for age, year of birth and
gender; 2- Adjusted for all of the variables in the column; 3-Ischeamic heart
disease or heart failure.4-Per 10-days increment; 5-Per increment of
ten hospitalizations.
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Clinical diagnosis
There was an overall increased incidence of hospitalisations
due to infectious diseases among COPD patients during
follow-up compared to the reference cohort, even for in-
fections of non-respiratory origin (e.g. endocarditis, skin
infections, septic arthritis and pyelonephritis), see Table 4.
Discussion
In this population-based study of 15,000 COPD patients,
we show that individuals discharged with a COPD diagno-
sis have a 2.5-fold increased incidence of invasive disease
from a wide range of bacterial pathogens compared to the
general population, independently of socio-economic status
and co-morbidities at base-line.
We hypothesized an increased incidence of invasive
diseases caused by bacteria associated with colonisation
of the airways in COPD, due to impaired barrier functions.
But increased incidence was also observed for other major
pathogens normally associated with non-respiratory infec-
tions, i.e., Staphylococcus aureus and enterobacteriaceae,
indicating a general susceptibility to invasive infections
of non-respiratory origin, which in turn could be due to
different mediating factors.
COPD is currently recognised as a disease with systemic
manifestations not limited to airflow obstruction and is
associated with several serious co-morbidities [9]. It is
therefore plausible to believe that COPD also confers
increased incidence of invasive bacterial infections of
non-respiratory origin. In contrast to our results, a Danish
study concluded that underlying COPD did not predict
hospitalizations due to infections outside the respiratory
system [10]. The study was based on 2,200 individuals
with COPD who were subdivided into GOLD classes
according to FEV1. Re-examining the incidence rates in
the Danish study does suggest an increased risk of hospi-
talisation for non-respiratory infectious diseases for COPD
as a group, although there was no clear trend of increased
risk with increasing GOLD stage. This classification, based
solely on FEV1, may not be sufficient to capture the full
effect of co-morbidities in COPD [11].
The increased incidence of infection in COPD could
also, to some extent, be mediated by the use of corticoste-
roids, anticholinergic inhalants or smoking. A limitation
of the present study is the lack of individual information
on COPD severity, corticosteroid use or smoking status
which is not available in the national databases.
The use of corticosteroids is an indisputable risk factor
for infection. However, risk estimates from observational
studies are limited by confounding by indication and the
nature of the underlying disease is an important modifier
of the infection risk, making it difficult to generalise
results from different disease groups [12]. In a pooled
analysis of 71 controlled clinical trials, a relative risk of
1.6 for infectious complications were reported in patients
given more than a cumulative dose of >700 mg prednisone
[12], but a stratified analysis of trials including patients
with pulmonary diseases showed no increased risk of
infectious complications [12]. Neither Smyllie et al. (case–
control study of 500 patients with respiratory diseases)
[13] nor Niewoehner et al. (randomised controlled trial of
oral steroid treatment for two or eight weeks in COPD),
found statistical significant differences in secondary infec-
tions [14]. In contrast, some meta-analyses of randomised
control trials have reported that treatment with inhaled
corticosteroids is associated with a 50-70% increased
risk of pneumonia [15,16]. However, no increased risk
was reported in pooled analyses of trials using budesonide
[17]. A side-effects of anticholinergic agents is urinary re-
tention, which can predispose to urinary tract infections.
Barr et al. (systematic meta-analysis of 3 clinical trials)
report an OR of 1.6 for urinary tract infections in users of
tiotropium vs. placebo [18].
Smokers have an increased risk of infectious complica-
tions but it is has not been shown that smoking is a risk
factor for bacteraemia not mediated through bacterial
colonization of the airways [19,20]. The comparisons in
Table 4 Incidence rates of hospitalizations for infectious diseases in the Inpatient Register for individuals previously
discharged with a COPD diagnosis and control subjects from the general population
COPD Control subjects
Type of infection N Incidence1 N Incidence1 HR2
Pnemonia 8,581 983 (963–1,004) 2,638 188 (181–195) 4.7 (4.4-4.9)
Skin infection 698 80 (74–86) 331 24 (21–26) 3.3 (2.8-3.8)
CNS infection 18 2.0 (1.3-3.2) 23 1.6 (1.1-2.4) 1.1 (0.6-2.3)3
Endocarditis 60 6.9 (5.3-8.9) 34 2.4 (1.7-3.4) 2.8 (1.7-4.7)
Pyelonephritis 500 57 (52–62) 300 22 (20–24) 2.4 (2.0-2.9)
Septic arthritis 93 10.7 (9.7-13.1) 80 5.7 (4.6-7.1) 1.9 (1.3-2.6)
1- Crude incidence of hospitalizations for infectious diseases per 10,000 person-years of follow-up. Infectious episodes were separated by >30 days for pneumonia,
skin infection, CNS infection and pyelonephritis and >60 days for endocarditis and septic arthritis. 2-Hazard ratio of time to first hospitalization for infection estimated by
Cox regression using time since inclusion as the time scale and stratified for age, year of birth and gender and adjusted for socio-economic status and co-morbidity.
3-Due to the limited number of outcomes, this Cox model was only adjusted for any co-morbidity (yes/no) prior to inclusion.
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the present study are not made between a smoking and
a non-smoking group; population-based studies of COPD
in Sweden have reported current smoking rates from 47%
(in 1992) to 34% (in 2004) in COPD patients compared to
33% and 13%, respectively, in non-COPD subjects in these
studies [21,22]. A survey of COPD patients in secondary
care (2007) showed that 23% were still smokers [23] com-
pared to national estimates of around 16% (2005) in the
adult population (>45 years of age) [24].
Register-based studies from national databases have
several advantages but also important limitations. The
study design, using a reference population that is ran-
domly drawn from the background population and stan-
dardised for age, gender, county, allows adjustments for
co-morbidity confounders, which is not possible in designs
based on national estimates, producing SIRs (standardised
incidence ratios).
The study covers all patients hospitalised with COPD
in Skåne during the observation period, but individuals
with COPD treated only as outpatients were not included
in the analysis. However, we found no effect modification
by the level of COPD diagnosis; thus risk estimates were
similar in subjects identified with COPD as main diagnosis
(hospitalised because of COPD) and as an additional one
(hospitalised with COPD). The prevalence of physician-
diagnosed COPD in Sweden is estimated to be 5-10%, and
in our study, 7.2% of the randomly selected general popu-
lation control subjects had a hospital discharge diagnosis
of COPD during the observation period. This result
implies that a large proportion of patients with COPD
will eventually be hospitalised either because or with
COPD.
General validation studies of the Swedish Inpatient
Registry indicate that the coverage is above 98% and that
almost 90% of the reported diagnoses are correct [25-27].
We have previously validated the COPD in this registry
[28]. The amount of evidence supporting the diagnosis
varied, but less than 10% were considered to be misclassi-
fied or having an uncertain COPD diagnosis. All stages of
COPD-severity were seen since patients were admitted
due to a number of reasons, not necessarily linked to
COPD, but the degree of validity did not differ between
COPD as a main or additional diagnosis. A misclassifi-
cation of the COPD-diagnosis in the present study, in
addition to the inclusion of COPD patients receiving only
outpatient care as control subjects, would presumably bias
the estimates downwards.
Diagnoses of infectious diseases from the Swedish
Inpatient Registry have not been validated separately,
except for infections in intensive care (CNS-infections,
pneumonia and sepsis) with the overall pattern of varying
sensitivity (38-99%) but high specificity (98.6-99.6%) [29].
The misclassification of clinical diagnosis are assumed
to be non-differential except for pneumonia, which could
theoretically be prone to increased misclassification in
COPD patients due to the sometimes diagnostic dilemma
to differ between episodes of exacerbation, heart failure or
pneumonia [30].
We adjusted our models for the use of inpatient care at
baseline and inpatient co-morbid conditions associated
with COPD and conferring increased risk of infection.
Residual confounding from co-morbid conditions requir-
ing only outpatient care cannot be ruled out.
In Sweden, there is as general recommendation to per-
form blood culture (at least) before treating patients with
intravenous antibiotics. Whether the adherence to these
guidelines is greater or less for COPD patients than for
individuals without COPD is not known. In the present
study the, hazard ratios were similar when using an in-
patient control group, indicating that the risk of ascertain-
ment bias is limited.
We conducted a population-based cohort study of the
incidence of severe bacterial infections in COPD patients
spanning 20 years covering all residents of the County of
Skåne, an area with approximately 1.2 million inhabitants.
We believe that the results are generalizable to many
settings, although differences in population composition
or access to health care are likely to influence the results.
Conclusion
This study shows that COPD patients have an overall
increased incidence of invasive bacterial infections com-
pared to the general population, indicating a general
susceptibility in addition to the specific susceptibility to
invasive infections of respiratory origin. The mediating
factors, smoking, corticosteroid use, co-morbid diseases or
a frailty inherent to COPD itself, and whether this propen-
sity influences the mortality rates, need to be disentangled
in further studies.
Consent
The study was approved by the Lund University Research
Ethics Committee (590/2004 and 270/2012). In accord-
ance with Swedish regulations, informed consent was not
obtained.
Appendix
Medical diagnoses in the Inpatient Registry and Cancer
Registry are coded according to the International Classifica-
tion of Disease, ninth and tenth revision, as follows: Liver
disease (ICD-8: 570, 571,90, 571,98, 571, 99, 573; ICD-9:
571E, 571 F, 571G, 571 W, 571X, 572–573; ICD-10:
K71-76), Renal failure (ICD-8: 582; ICD-9: 585–586;
ICD-10: N18-19), Chronic obstructive pulmonary disease
(COPD) (ICD-8: 491–492; ICD-9:491–492, 496; ICD-10:
J41-J44), Heart failure: ICD-8: 427,00, 428; ICD-9: 428;
ICD-10: I50, Ischemic heart disease: ICD-8: 410–414;
ICD-9: 410–414; ICD-10: I20-I25), HIV (ICD-9: 279 K,
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V02J; ICD-10:B20-24; Immuno-deficiency (ICD-8: 288,
275,00, 275,10; ICD-9: 279 J,L,M,N,W,X; ICD-10:D70,
D71, D80-84), Connective tissue disease (ICD-8: 712,
714,93, 716,734; ICD-9: 710, 714, 720, 725; ICD-10:
M30-35, M05-09), Alcohol-related disease (ICD-8: 291,
303; 980, 571,00, 571, 01; ICD-9: 291, 303, 305A,357 F,
571A, 571B, 571C, 571D, 980A; ICD-10: F10, K70, E512,
G312, G621, G721, K852, K860, X45, T45, Z714), Diabetes
mellitus (ICD-8: 250; ICD-9: 250; ICD-10: E10-E11),
Haematological cancer (ICD-7:200–204, ICD-9: 200–208;
ICD-10: C81-C96, D46), Solid cancer (ICD-7: 140–199;
ICD-9: 140–199, 230–234, ICD-10: C00-C81, D00-D09).
Pneumonia (ICD-9:481–483, 486; ICD-10:A48.1, B01.2,
J13-J16, J18). Skin infections (ICD-9:035, 040A; ICD-10:
A46, A48.0). Pyelonephritis (ICD-9:590; ICD-10:N10).
Septic arthritis (ICD-9: 711A, 730A; ICD-10:M00, M01.0,
M46.2-3, M46.5, M86.0). Endocarditis (ICD-9:421; ICD-
10: I33). CNS infection (ICD-9:320, 324; ICD-10:A39.0,
G00-01, G06).
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